Form D · Pharmaceuticals
Alitair Pharmaceuticals, Inc.
Morristown, NJ · CIK 0001654448
Offering snapshot reported Nov 13, 2020 · SEC filing
- Reported sold
- $35K Offering amount: $31M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Oct 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2020 | Initial | $35,000 | No comparison | 3 | SEC filing |
| Oct 9, 2018 | Initial | $115,000 | No comparison | 3 | SEC filing |
| Jul 3, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 10, 2017 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Sep 30, 2015 | Initial | $910,834 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-380521
Source: Form D, filed Nov 13, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Casale | Director |
| Frank Guarino | Executive |
| William W. Howard | Director, Executive |
| James E. Hoyes | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
55 Madison Street Suite 400
Morristown, NJ, 07960
Morristown, NJ, 07960